Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics

Human Molecular Genetics

Volumn 25, Issue 20, 2016, Pages 4590-4600

  Strug, Lisa J ^a,b,c   Gonska, Tanja ^b,d   He, Gengming ^a   Keenan, Katherine ^d   Ip, Wan ^d   Böelle, Pierre Yves ^e,f   Lin, Fan ^a   Panjwani, Naim ^a   Gong, Jiafen ^a   Li, Weili ^a,c   Soave, David ^a,b   Xiao, Bowei ^a   Tullis, Elizabeth ^g   Rabin, Harvey ^h,i   Parkins, Michael D ^h,i   Price, April ^j   Zuberbuhler, Peter C ^k   Corvol, Harriet ^e,l   Ratjen, Felix ^d   Sun, Lei ^b   Bear, Christine E ^d,m   Rommens, Johanna M ^a,m   more..

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e SORBONNE UNIVERSITÉ   (France)

^f HÔPITAL SAINT ANTOINE   (France)

^g ST MICHAEL'S HOSPITAL   (Canada)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ UNIVERSITY OF CALGARY   (Canada)

^j LONDON HEALTH SCIENCES CENTRE   (Canada)

^k UNIVERSITY OF ALBERTA   (Canada)

^l ARMAND TROUSSEAU HOSPITAL   (France)

^m UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; LUMACAFTOR; PHENYLALANINE; SLC26A9 PROTEIN; SOLUTE CARRIER PROTEIN; UNCLASSIFIED DRUG; AMINOPHENOL DERIVATIVE; ANTIPORTER; CFTR PROTEIN, HUMAN; CHLORIDE CHANNEL STIMULATING AGENT; QUINOLONE DERIVATIVE; SLC26A9 PROTEIN, HUMAN;

ADULT; AIRWAY; ARTICLE; BRONCHUS; CELL SURFACE; CHANNEL GATING; COMPASSIONATE USE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE SEVERITY; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HOMOZYGOTE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG FIBROSIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; MODIFIER GENE; MULTICENTER STUDY; PRIORITY JOURNAL; PROBABILITY; TREATMENT RESPONSE; AGONISTS; BIOLOGICAL MODEL; CANADA; CELL CULTURE; DRUG EFFECTS; FEMALE; FRANCE; GENETIC ASSOCIATION STUDY; GENETICS; LUNG; MALE; METABOLISM; PATHOLOGY; PATIENT ACUITY; PERSONALIZED MEDICINE; PHARMACOGENETIC VARIANT; SINGLE NUCLEOTIDE POLYMORPHISM;

AMINOPHENOLS; ANTIPORTERS; CANADA; CELLS, CULTURED; CHLORIDE CHANNEL AGONISTS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; FRANCE; GENES, MODIFIER; GENETIC ASSOCIATION STUDIES; HUMANS; LUNG; MALE; MODELS, GENETIC; PATIENT ACUITY; PHARMACOGENOMIC VARIANTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECISION MEDICINE; QUINOLONES;

EID: 85014409703     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddw290     Document Type: Article

References (60)

1. Sanders, D.B., Li, Z., Laxova, A., Rock, M.J., Levy, H., Collins, J., Ferec, C. and Farrell, P.M. (2014) Risk factors for the progression of cystic fibrosis lung disease throughout childhood. Ann. Am. Thorac. Soc, 11, 63-72.
2. Collaco, J.M., Vanscoy, L., Bremer, L., McDougal, K., Blackman, S.M., Bowers, A., Naughton, K., Jennings, J., Ellen, J. and Cutting, G.R. (2008) Interactions between secondhand smoke and genes that affect cystic fibrosis lung disease. JAMA, 299, 417-424.
3. Goss, C.H., Newsom, S.A., Schildcrout, J.S., Sheppard, L. and Kaufman, J.D. (2004) Effect of ambient air pollution on pulmonary exacerbations and lung function in cystic fibrosis. Am. J. Respir. Crit. Care Med., 169, 816-821.
4. Cutting, G.R. (2015) Cystic fibrosis genetics: from molecular understanding to clinical application. Nat. Rev. Genet., 16, 45-56.
5. Soave, D., Corvol, H., Panjwani, N., Gong, J., Li, W., Böelle, P.Y., Durie, P.R., Paterson, A.D., Rommens, J.M., Strug, L.J., et al. (2015) A Joint Location-Scale Test Improves Power to Detect Associated SNPs, Gene Sets, and Pathways. Am. J. Hum. Genet., 97, 125-138.
6. Corvol, H., Blackman, S., Böelle, P., Gallins, P., Pace, R., Stonebraker, J., Accurso, F., Clement, A., Collaco, J., Dang, H., et al. (2015) Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis. Nature Commun, 6, 8382.
7. Ratjen, F., Bell, S.C., Rowe, S.M., Goss, C.H., Quittner, A.L. and Bush, A. (2015) Cystic fibrosis. Nat. Rev. Dis. Primers, 1, 1-19.
8. Sosnay, P.R., Siklosi, K.R., Van Goor, F., Kaniecki, K., Yu, H., Sharma, N., Ramalho, A.S., Amaral, M.D., Dorfman, R., Zielenski, J., et al. (2013) Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat. Genet., 45, 1160-1167.
9. Rabeh, W.M., Bossard, F., Xu, H., Okiyoneda, T., Bagdany, M., Mulvihill, C.M., Du, K., di Bernardo, S., Liu, Y., Konermann, L., et al. (2012) Correction of both NBD1 energetics and domain interface is required to restore DeltaF508 CFTR folding and function. Cell, 148, 150-163.
10. Thibodeau, P.H., Richardson, J.M., 3rd, Wang, W., Millen, L., Watson, J., Mendoza, J.L., Du, K., Fischman, S., Senderowitz, H., Lukacs, G.L., et al. (2010) The cystic fibrosis-causing mutation deltaF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis. J. Biol. Chem., 285, 35825-35835.
11. Dalemans, W., Barbry, P., Champigny, G., Jallat, S., Dott, K., Dreyer, D., Crystal, R.G., Pavirani, A., Lecocq, J.P. and Lazdunski, M. (1991) Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature, 354, 526-528.
12. Sharma, M., Pampinella, F., Nemes, C., Benharouga, M., So, J., Du, K., Bache, K.G., Papsin, B., Zerangue, N., Stenmark, H., et al. (2004) Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes. J. Cell. Biol., 164, 923-933.
13. Bobadilla, J.L., Macek, M., Jr., Fine, J.P. and Farrell, P.M. (2002) Cystic fibrosis: a worldwide analysis of CFTR mutations-correlation with incidence data and application to screening. Hum. Mutat., 19, 575-606.
14. Bompadre, S.G., Sohma, Y., Li, M. and Hwang, T.C. (2007) G551D and G1349D, two CF-associated mutations in the signature sequences of CFTR, exhibit distinct gating defects. J. Gen. Physiol., 129, 285-298.
15. Ramjeesingh, M., Ugwu, F., Stratford, F.L., Huan, L.J., Li, C. and Bear, C.E. (2008) The intact CFTR protein mediates ATPase rather than adenylate kinase activity. Biochem. J., 412, 315-321.
16. Van Goor, F., Hadida, S., Grootenhuis, P.D., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A., Joubran, J., Hazlewood, A., et al. (2009) Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl. Acad. Sci. USA, 106, 18825-18830.
17. Ramsey, B.W., Davies, J., McElvaney, N.G., Tullis, E., Bell, S.C., Drevinek, P., Griese, M., McKone, E.F., Wainwright, C.E., Konstan, M.W., et al. (2011) A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med., 365, 1663-1672.
18. Yu, H., Burton, B., Huang, C.J., Worley, J., Cao, D., Johnson, J.P., Jr., Urrutia, A., Joubran, J., Seepersaud, S., Sussky, K., et al. (2012) Ivacaftor potentiation of multiple CFTR channels with gating mutations. J. Cyst. Fibros., 11, 237-245.
19. Wainwright, C.E., Elborn, J.S., Ramsey, B.W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., Davies, J.C., De Boeck, K., Flume, P.A., et al. (2015) Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N. Engl. J. Med., 373, 220-231.
20. Durmowicz, A.G., Witzmann, K.A., Rosebraugh, C.J. and Chowdhury, B.A. (2013) Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience. Chest, 143, 14-18.
21. Chang, M.H., Plata, C., Sindic, A., Ranatunga, W.K., Chen, A.P., Zandi-Nejad, K., Chan, K.W., Thompson, J., Mount, D.B. and Romero, M.F. (2009) Slc26a9 Is Inhibited by the R-region of the Cystic Fibrosis Transmembrane Conductance Regulator via the STAS Domain. J. Biol. Chem., 284, 28306-28318.
22. Loriol, C., Dulong, S., Avella, M., Gabillat, N., Boulukos, K., Borgese, F. and Ehrenfeld, J. (2008) Characterization of SLC26A9, facilitation of Cl(-) transport by bicarbonate. Cell Physiol. Biochem., 22, 15-30.
23. Ohana, E., Yang, D., Shcheynikov, N. and Muallem, S. (2009) Diverse transport modes by the solute carrier 26 family of anion transporters. J. Physiol., 587, 2179-2185.
24. Bertrand, C.A., Zhang, R., Pilewski, J.M. and Frizzell, R.A. (2009) SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epithelia. J. Gen. Physiol., 133, 421-438.
25. Avella, M., Loriol, C., Boulukos, K., Borgese, F. and Ehrenfeld, J. (2011) SLC26A9 stimulates CFTR expression and function in human bronchial cell lines. J. Cell Physiol., 226, 212-223.
26. Ousingsawat, J., Schreiber, R. and Kunzelmann, K. (2011) Differential Contribution of SLC26A9 to Cl-conductance in polarized and non-polarized epithelial cells. Cell Physiol. Biochem., 227, 2323-2329.
27. Liu, X., Li, T., Riederer, B., Lenzen, H., Ludolph, L., Yeruva, S., Tuo, B., Soleimani, M. and Seidler, U. (2015) Loss of Slc26a9 anion transporter alters intestinal electrolyte and HCO3(-) transport and reduces survival in CFTR-deficient mice. Pflugers Arch., 467, 1261-1275.
28. Soave, D., Miller, M.R., Keenan, K., Li, W., Gong, J., Ip, W., Accurso, F., Sun, L., Rommens, J.M., Sontag, M., et al. (2014) Evidence for a causal relationship between early exocrine pancreatic disease and cystic fibrosis-related diabetes: a Mendelian randomization study. Diabetes, 63, 2114-2119.
29. Sun, L., Rommens, J.M., Corvol, H., Li, W., Li, X., Chiang, T.A., Lin, F., Dorfman, R., Busson, P.F., Parekh, R.V., et al. (2012) Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. Nat. Genet., 44, 562-569.
30. Miller, M.R., Soave, D., Li, W., Gong, J., Pace, R.G., Böelle, P.Y., Cutting, G.R., Drumm, M.L., Knowles, M.R., Sun, L., et al. (2015) Variants in Solute Carrier SLC26A9 Modify Prenatal Exocrine Pancreatic Damage in Cystic Fibrosis. J. Pediatr., 166, 1152-1157. e1156.
31. Wright, F.A., Strug, L.J., Doshi, V.K., Commander, C.W., Blackman, S.M., Sun, L., Berthiaume, Y., Cutler, D., Cojocaru, A., Collaco, J.M., et al. (2011) Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat. Genet., 43, 539-546.
32. Li, W., Soave, D., Miller, M.R., Keenan, K., Lin, F., Gong, J., Chiang, T., Stephenson, A.L., Durie, P., Rommens, J., et al. (2014) Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities. Hum. Genet., 133, 151-161.
33. GTEx Consortium. (2015) The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science, 348, 648-660.
34. Lonsdale, J., Thomas, J., et al. (2013) The Genotype-Tissue Expression (GTEx) project. Nat. Genet., 45, 580-585.
35. Braun, J., Mundhenk, L., Range, F. and Gruber, A.D. (2010) Quantitative expression analyses of candidates for alternative anion conductance in cystic fibrosis mouse models. J. Cyst. Fibros., 9, 351-364.
36. Dorfman, R., Sandford, A., Taylor, C., Huang, B., Frangolias, D., Wang, Y., Sang, R., Pereira, L., Sun, L., Berthiaume, Y., et al. (2008) Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J. Clin. Invest., 118, 1040-1049.
37. Taylor, C., Commander, C.W., Collaco, J.M., Strug, L.J., Li, W., Wright, F.A., Webel, A.D., Pace, R.G., Stonebraker, J.R., Naughton, K., et al. (2011) A novel lung disease phenotype adjusted for mortality attrition for cystic fibrosis Genetic modifier studies. Pediatr. Pulmonol., 46, 857-869.
38. Kulich, M., Rosenfeld, M., Campbell, J., Kronmal, R., Gibson, R.L., Goss, C.H. and Ramsey, B. (2005) Disease-specific reference equations for lung function in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med., 172, 885-891.
39. Blackman, S., Commander, C., Watson, C., Arcara, K., Strug, L., Stonebraker, J., Wright, F., Rommens, J., Sun, L., Pace, R., et al. (2013) Genetic modifiers of cystic fibrosis-related diabetes. Diabetes, 62, 3627-3635.
40. Roadmap Epigenomics Consortium, Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., et al. (2015) Integrative analysis of 111 reference human epigenomes. Nature, 518, 317-330.
41. Ernst, J. and Kellis, M. (2012) ChromHMM: automating chromatin-state discovery and characterization. Nat. Methods, 9, 215-216.
42. Encode Project Consortium. (2012) An integrated encyclopedia of DNA elements in the human genome. Nature, 489, 57-74.
43. Mall, M.A. and Galietta, L.J. (2015) Targeting ion channels in cystic fibrosis. J. Cyst. Fibros., 14, 561-570.
44. El Khouri, E. and Toure, A. (2014) Functional interaction of the cystic fibrosis transmembrane conductance regulator with members of the SLC26 family of anion transporters (SLC26A8 and SLC26A9): physiological and pathophysiological relevance. Int. J. Biochem. Cell Biol., 52, 58-67.
45. Anagnostopoulou, P., Riederer, B., Duerr, J., Michel, S., Binia, A., Agrawal, R., Liu, X., Kalitzki, K., Xiao, F., Chen, M., et al. (2012) SLC26A9-mediated chloride secretion prevents mucus obstruction in airway inflammation. J. Clin. Invest., 122, 3629-3634.
46. Bakouh, N., Bienvenu, T., Thomas, A., Ehrenfeld, J., Liote, H., Roussel, D., Duquesnoy, P., Farman, N., Viel, M., Cherif-Zahar, B., et al. (2013) Characterization of SLC26A9 in patients with CF-like lung disease. Hum. Mutat., 34, 1404-1414.
47. Bienvenu, T., Sermet-Gaudelus, I., Burgel, P.R., Hubert, D., Crestani, B., Bassinet, L., Dusser, D. and Fajac, I. (2010) Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care. Med., 181, 1078-1084.
48. Casals, T., De-Gracia, J., Gallego, M., Dorca, J., Rodriguez-Sanchon, B., Ramos, M.D., Gimenez, J., Cistero-Bahima, A., Olveira, C. and Estivill, X. (2004) Bronchiectasis in adult patients: an expression of heterozygosity for CFTR gene mutations?. Clin. Genet., 65, 490-495.
49. Girodon, E., Cazeneuve, C., Lebargy, F., Chinet, T., Costes, B., Ghanem, N., Martin, J., Lemay, S., Scheid, P., Housset, B., et al. (1997) CFTR gene mutations in adults with disseminated bronchiectasis. Eur. J. Hum. Genet., 5, 149-155.
50. Bergougnoux, A., Viart, V., Miro, J., Bommart, S., Molinari, N., des Georges, M., Claustres, M., Chiron, R. and Taulan-Cadars, M. (2015) Should diffuse bronchiectasis still be considered a CFTR-related disorder?. J. Cyst. Fibros., 14, 646-653.
51. Stanojevic, S., Wade, A., Stocks, J., Hankinson, J., Coates, A.L., Pan, H., Rosenthal, M., Corey, M., Lebecque, P. and Cole, T.J. (2008) Reference ranges for spirometry across all ages: a new approach. Am. J. Respir. Crit. Care Med., 177, 253-260.
52. Eckford, P.D., Ramjeesingh, M., Molinski, S., Pasyk, S., Dekkers, J.F., Li, C., Ahmadi, S., Ip, W., Chung, T.E., Du, K., et al. (2014) VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface. Chem. Biol., 21, 666-678.
53. Cao, H., Ouyang, H., Ip, W., Du, K., Duan, W., Avolio, J., Wu, J., Duan, C., Yeger, H., Bear, C., et al. (2015) Testing gene therapy vectors in human primary nasal epithelial cultures. Mol. Ther. Methods. Clin. Dev., doi:10.1038/mtm.2015.34.
54. Yang, H., Shelat, A.A., Guy, R.K., Gopinath, V.S., Ma, T., Du, K., Lukacs, G.L., Taddei, A., Folli, C., Pedemonte, N., et al. (2003) Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating. J. Biol. Chem., 278, 35079-35085.
55. Tourlakis, M.E., Zhong, J., Gandhi, R., Zhang, S., Chen, L., Durie, P.R. and Rommens, J.M. (2012) Deficiency of Sbds in the mouse pancreas leads to features of Shwachman-Diamond syndrome, with loss of zymogen granules. Gastroenterology, 143, 481-492.
56. Speir, M.L., Zweig, A.S., Rosenbloom, K.R., Raney, B.J., Paten, B., Nejad, P., Lee, B.T., Learned, K., Karolchik, D., Hinrichs, A.S., et al. (2015) The UCSC Genome Browser database: 2016 update. Nucleic Acids Res., 44, D717-25.
57. Encode Project Consortium. (2011) A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol, 9, e1001046.
58. Griffon, A., Barbier, Q., Dalino, J., van Helden, J., Spicuglia, S. and Ballester, B. (2015) Integrative analysis of public ChIPseq experiments reveals a complex multi-cell regulatory landscape. Nucleic Acids Res., 43, e27.
59. Barrett, J.C., Fry, B., Maller, J. and Daly, M.J. (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics, 21, 263-265.
60. Pollard, K.S., Hubisz, M.J., Rosenbloom, K.R. and Siepel, A. (2010) Detection of nonneutral substitution rates on mammalian phylogenies. Genome Res., 20, 110-121.